Literature DB >> 1571264

Malignant Langerhans cell tumour.

M Tani1, N Ishii, M Kumagai, M Ban, A Sasase, Y Mishima.   

Abstract

We report the case of a 49-year-old woman suffering from a malignant neoplasm of Langerhans cells (LC), documented by immunohistochemical and ultrastructural analysis, and review the literature to examine and characterize the clinical and laboratory features, therapy, and prognosis of malignant neoplasms of LC. Langerhans cell histiocytosis is now regarded as a disorder of immune regulation or an inflammatory process, rather than as a malignant neoplasm. Although LC share certain features in common with ordinary histiocytes or interdigitating dendritic cells, they also differ significantly from these cells in other respects. Therefore, we propose designating a malignant neoplasm of LC 'malignant Langerhans cell tumour' and that it should be considered as a separate entity from Langerhans cell histiocytosis or other malignant histiocytoses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1571264     DOI: 10.1111/j.1365-2133.1992.tb00689.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

1.  Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature.

Authors:  Boris Dominik Jülg; Sven Weidner; Doris Mayr
Journal:  Virchows Arch       Date:  2005-11-22       Impact factor: 4.064

Review 2.  Cutaneous Langerhans cell sarcoma: a case report and review of the literature.

Authors:  Olga L Bohn; Guillermo Ruiz-Argüelles; Leticia Navarro; Jesus Saldivar; Sergio Sanchez-Sosa
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

3.  Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report.

Authors:  Jong-Sil Lee; Gyung Hyuck Ko; Ho Cheol Kim; In Seok Jang; Kyung-Nyeo Jeon; Jeong-Hee Lee
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

4.  ESHAP therapy effective in a patient with Langerhans cell sarcoma.

Authors:  Akihide Yoshimi; Keiki Kumano; Toru Motokura; Yutaka Takazawa; Satoshi Oota; Shigeru Chiba; Tsuyoshi Takahashi; Masashi Fukayama; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2008-04-17       Impact factor: 2.490

5.  Langerhans Cell Sarcoma of the Axillary Lymph Node: A Case Report and Review of the Literature.

Authors:  Aylin Orgen Çallı; Yelda Morgül; İnci Alacacıoğlu; Sadi Bener; Bahriye Payzin
Journal:  Turk J Haematol       Date:  2013-06-05       Impact factor: 1.831

6.  Langerhans cell sarcoma originating from left knee subcutaneous tissue: A case report and literature review.

Authors:  Yaonan Zhang; Zongyang Qu; Fang Fang
Journal:  Oncol Lett       Date:  2016-09-27       Impact factor: 2.967

7.  Unusual cutaneous Langerhans cell sarcoma without extracutaneous involvement.

Authors:  Yang Li; Bin Li; Xiao-ying Tian; Zhi Li
Journal:  Diagn Pathol       Date:  2013-02-06       Impact factor: 2.644

8.  Epstein-Barr Virus-Positive Langerhans Cell Sarcoma: Is There a Link? A Case Report.

Authors:  Yu Guo; Shui-Hong Zhou; Zai-Zai Cao; Yang-Yang Bao; Li-Fang Shen; Hong-Tian Yao
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.